Mandate

Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma

November 03, 2016

Medivir AB (publ) (Nasdaq Stockholm) has entered into an agreement with Karo Pharma AB (publ) (Nasdaq Stockholm) regarding the sale of Medivir’s subsidiary BioPhausia (Nordic Brands) to Karo Pharma. The purchase price is SEK 908 million and the transaction is expected to close by mid-December 2016.
 
Vinge advises Medivir. The Vinge team includes Erik Sjöman, Anna Edström, Mattias Sköld, Dain Hård Nevonen, Rikard Lindahl and Ludvig Frithiof, and Fredrik Dahl and Sara Strandberg (employment law).

Related

Vinge advises KEYTO Group in connection with the acqusition of Säkra Larm

KEYTO Group continues to broaden its home services offering as Säkra Larm joins the Group, establishing home security as a new business vertical within KEYTO. The addition marks another important step in KEYTO's ambition to become the leading one-stop destination for services connected to the home.
September 24, 2026

Vinge has advised Ingrid Capacity in connection with the formation of a strategic partnership with Mirova for a strategic partnership for a large-scale BESS portfolio in the Nordics

Ingrid Capacity and Mirova, an affiliate of Natixis Investment Managers dedicated to sustainable investment, announce a cross-border partnership of two BESS projects totalling 145 MW/290 MWh in Sweden and Finland. Vinge has advised Ingrid Capacity in connection with the formation of the partnership.
September 24, 2026

Vinge advises the financing banks in connection with Verdane and Telenor’s partnership in Telenor Connexion

Vinge has advised a syndicate of Nordic and Northern European banks connection with the financing of Verdane and Telenor’s new partnership relating to Telenor Connexion. Under the partnership, Verdane and Telenor will jointly invest in Telenor Connexion, a leading provider of IoT solutions. The transaction was completed on 10 September 2026 and values Telenor Connexion at SEK 7.5 billion.
September 23, 2026